Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Margaret Wierman and Katja Kiseljak-Vassiliades.

 
Connection Strength
  
 
 
7.470
  
  1. Kiseljak-Vassiliades K, Lipe K, Turin CG, Fishbein L, Costello JC, Kerr JM, Holmstoen TB, Youssef AS, Lillehei KO, Kleinschmidt-DeMasters BK, Wierman ME. E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes. J Neuropathol Exp Neurol. 2024 Jun 20; 83(7):586-595.
    View in: PubMed
    Score: 0.910
  2. Wierman ME, Kiseljak-Vassiliades K. Should Dehydroepiandrosterone Be Administered to Women? J Clin Endocrinol Metab. 2022 05 17; 107(6):1679-1685.
    View in: PubMed
    Score: 0.787
  3. Kiseljak-Vassiliades K, Zhang Y, Kar A, Razzaghi R, Xu M, Gowan K, Raeburn CD, Albuja-Cruz M, Jones KL, Somerset H, Fishbein L, Leong S, Wierman ME. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology. 2018 07 01; 159(7):2532-2544.
    View in: PubMed
    Score: 0.601
  4. Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 04; 25(4):437-451.
    View in: PubMed
    Score: 0.584
  5. Kiseljak-Vassiliades K, Mills TS, Zhang Y, Xu M, Lillehei KO, Kleinschmidt-DeMasters BK, Wierman ME. Elucidating the Role of the Desmosome Protein p53 Apoptosis Effector Related to PMP-22 in Growth Hormone Tumors. Endocrinology. 2017 05 01; 158(5):1450-1460.
    View in: PubMed
    Score: 0.555
  6. Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol. 2015 Dec 05; 417:73-83.
    View in: PubMed
    Score: 0.496
  7. Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Lillehei KO, Kerr JM, Wierman ME. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. 2015 May; 49(1):231-41.
    View in: PubMed
    Score: 0.460
  8. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME. Clinical implications of growth hormone-secreting tumor subtypes. Endocrine. 2012 Aug; 42(1):18-28.
    View in: PubMed
    Score: 0.389
  9. Holmstoen TB, Volino LK, Molina Kuna E, Banerjee T, Fishbein L, Wierman ME, Kiseljak-Vassiliades K. Geographical Variation in Adrenocortical Carcinoma Incidence Across Colorado. J Endocr Soc. 2025 May; 9(5):bvaf057.
    View in: PubMed
    Score: 0.240
  10. Tahmasbi Sohi M, Cali M, Forster JE, Kiseljak-Vassiliades K, Wierman ME. Short term effects of intraarticular triamcinolone acetonide injection on serum testosterone, luteinizing hormone, and follicle stimulating hormone levels in male veterans: A prospective pilot study. PM R. 2024 Jan; 16(1):6-13.
    View in: PubMed
    Score: 0.212
  11. Pozdeyev N, Fishbein L, Gay LM, Sokol ES, Hartmaier R, Ross JS, Darabi S, Demeure MJ, Kar A, Foust LJ, Koc K, Bowles DW, Leong S, Wierman ME, Kiseljak-Vassiliades K. Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr Relat Cancer. 2021 08 16; 28(10):671-681.
    View in: PubMed
    Score: 0.187
  12. Kar A, Wierman ME, Kiseljak-Vassiliades K. Update on in-vivo preclinical research models in adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2020 06; 27(3):170-176.
    View in: PubMed
    Score: 0.172
  13. Schreiber AR, Kar A, Goodspeed AE, Pozdeyev N, Somerset H, Raeburn CD, Tan AC, Leong S, Wierman ME, Kiseljak-Vassiliades K. Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report. J Endocr Soc. 2020 Mar 01; 4(3):bvaa017.
    View in: PubMed
    Score: 0.168
  14. Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, Messersmith WA, Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. J Clin Endocrinol Metab. 2020 01 01; 105(1).
    View in: PubMed
    Score: 0.167
  15. Kar A, Zhang Y, Yacob BW, Saeed J, Tompkins KD, Bagby SM, Pitts TM, Somerset H, Leong S, Wierman ME, Kiseljak-Vassiliades K. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocr Relat Cancer. 2019 10; 26(10):765-778.
    View in: PubMed
    Score: 0.164
  16. Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K, Reigan P, Wierman ME. Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. Mol Cancer Ther. 2016 Mar; 15(3):412-20.
    View in: PubMed
    Score: 0.126
  17. Xiong W, Knox AJ, Xu M, Kiseljak-Vassiliades K, Colgan SP, Brodsky KS, Kleinschmidt-Demasters BK, Lillehei KO, Wierman ME. Mammalian Ste20-like kinase 4 promotes pituitary cell proliferation and survival under hypoxia. Mol Endocrinol. 2015 Mar; 29(3):460-72.
    View in: PubMed
    Score: 0.119
  18. Xu M, Knox AJ, Michaelis KA, Kiseljak-Vassiliades K, Kleinschmidt-DeMasters BK, Lillehei KO, Wierman ME. Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology. 2012 Jul; 153(7):2963-73.
    View in: PubMed
    Score: 0.098
  19. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, Geraci M, Kleinschmidt-DeMasters BK, Lillehei KO, Wierman ME. Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology. 2011 Oct; 152(10):3603-13.
    View in: PubMed
    Score: 0.093
  20. Wierman ME, Kiseljak-Vassiliades K, Tobet S. Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function. Front Neuroendocrinol. 2011 Jan; 32(1):43-52.
    View in: PubMed
    Score: 0.087
  21. Chan YS, Gao Q, Robinson SA, Wang W, Filandrova R, Weinhold LM, Cabrera ML, Zhang M, Ambati CSR, Lerario AM, Putluri N, Kiseljak-Vassiliades K, Wierman ME, Habra MA, Hammer GD, Veverka V, Cermakova K, Hodges HC. ß-catenin functions as a molecular adapter for disordered cBAF interactions. Mol Cell. 2025 Aug 21; 85(16):3041-3056.e9.
    View in: PubMed
    Score: 0.061
  22. Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.
    View in: PubMed
    Score: 0.061
  23. Turin CG, Kiseljak-Vassiliades K, Wierman ME, Lillehei K, Kleinschmidt-DeMasters BK. Clinical features of plurihormonal pituitary adenoma subtypes. Endocr Relat Cancer. 2025 Jul 01; 32(7).
    View in: PubMed
    Score: 0.061
  24. Mariniello K, Pittaway JFH, Altieri B, Borges KS, Hadjidemetriou I, Ribeiro C, Ruiz-Babot G, Tourigny DS, Lim JA, Foster J, Cleaver J, Sosabowski J, Rahman N, Doroszko M, Hantel C, Sigala S, Abate A, Tamburello M, Kiseljak-Vassiliades K, Wierman M, Hall C, Parvanta L, Abdel-Aziz TE, Chung TT, Marco AD, Palazzo F, Gomez-Sanchez CE, Taylor DR, Rayner O, Ronchi CL, Gaston-Massuet C, Sbiera S, Drake WM, Rognoni E, Kroiss M, Breault DT, Fassnacht M, Guasti L. Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. Cancer Commun (Lond). 2025 Jun; 45(6):663-668.
    View in: PubMed
    Score: 0.060
  25. Subramanian C, McNamara K, Croslow SW, Tan Y, Hess D, Kiseljak-Vassiliades K, Wierman ME, Sweedler JV, Cohen MS. Novel repurposing of sulfasalazine for the treatment of adrenocortical carcinomas, probably through the SLC7A11/xCT-hsa-miR-92a-3p-OIP5-AS1 network pathway. Surgery. 2025 01; 177:108832.
    View in: PubMed
    Score: 0.058
  26. Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S, Roper N, Reinhold WC, Robey RW, Takebe N, Gottesman MM, Thomas CJ, Boeva V, Berruti A, Abate A, Tamburello M, Sigala S, Hantel C, Weigand I, Wierman ME, Kiseljak-Vassiliades K, Del Rivero J, Pommier Y. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
    View in: PubMed
    Score: 0.058
  27. Mariniello K, Pittaway JFH, Altieri B, Borges KS, Hadjidemetriou I, Ribeiro C, Ruiz-Babot G, Lim JA, Foster J, Cleaver J, Sosabowski J, Rahman N, Doroszko M, Hantel C, Sigala S, Abate A, Tamburello M, Kiseljak-Vassiliades K, Wierman M, Parvanta L, Abdel-Aziz TE, Chung TT, Di Marco A, Palazzo F, Gomez-Sanchez CE, Taylor DR, Rayner O, Ronchi CL, Gaston-Massuet C, Sbiera S, Drake WM, Rognoni E, Kroiss M, Breault DT, Fassnacht M, Guasti L. Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. bioRxiv. 2024 Aug 22.
    View in: PubMed
    Score: 0.058
  28. Warmington E, Smith G, Chortis V, Liang R, Lippert J, Steinhauer S, Landwehr LS, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Altieri B, Foster PA, Ronchi CL. PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. Endocr Connect. 2024 Jan 01; 13(1).
    View in: PubMed
    Score: 0.055
  29. McDonald HG, Sarvestani AL, Owen JW, Rueckert J, Wierman ME, Kiseljak-Vassiliades K, Pandalai PK, Ellis CS, Patel RA, Del Rivero J, Hernandez JM, Cavnar MJ. Response of adrenocortical carcinoma liver metastases to hepatic artery infusion floxuridine. HPB (Oxford). 2023 11; 25(11):1446-1449.
    View in: PubMed
    Score: 0.053
  30. Ruggiero C, Tamburello M, Rossini E, Zini S, Durand N, Cantini G, Cioppi F, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Landwehr LS, Weigand I, Kurlbaum M, Zizioli D, Turtoi A, Yang S, Berruti A, Luconi M, Sigala S, Lalli E. FSCN1 as a new druggable target in adrenocortical carcinoma. Int J Cancer. 2023 07 01; 153(1):210-223.
    View in: PubMed
    Score: 0.052
  31. Alzofon N, Koc K, Panwell K, Pozdeyev N, Marshall CB, Albuja-Cruz M, Raeburn CD, Nathanson KL, Cohen DL, Wierman ME, Kiseljak-Vassiliades K, Fishbein L. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. Mol Cancer Res. 2021 09; 19(9):1476-1485.
    View in: PubMed
    Score: 0.046
  32. Maria AG, Silva Borges K, Lira RCP, Hassib Thom? C, Berthon A, Drougat L, Kiseljak-Vassiliades K, Wierman ME, Faucz FR, Fa?a VM, Tone LG, Stratakis CA. Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells. Mol Cell Endocrinol. 2021 05 15; 528:111243.
    View in: PubMed
    Score: 0.045
  33. Weigand I, Schreiner J, R?hrig F, Sun N, Landwehr LS, Urlaub H, Kendl S, Kiseljak-Vassiliades K, Wierman ME, Angeli JPF, Walch A, Sbiera S, Fassnacht M, Kroiss M. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 2020 03 17; 11(3):192.
    View in: PubMed
    Score: 0.042
  34. Head L, Kiseljak-Vassiliades K, Clark TJ, Somerset H, King J, Raeburn C, Albuja-Cruz M, Weyant M, Cleveland J, Wierman ME, Leong S. Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer. J Endocr Soc. 2019 Dec 01; 3(12):2295-2304.
    View in: PubMed
    Score: 0.041
  35. Hadjidemetriou I, Mariniello K, Ruiz-Babot G, Pittaway J, Mancini A, Mariannis D, Gomez-Sanchez CE, Parvanta L, Drake WM, Chung TT, Abdel-Aziz TE, DiMarco A, Palazzo FF, Wierman ME, Kiseljak-Vassiliades K, King PJ, Guasti L. DLK1/PREF1 marks a novel cell population in the human adrenal cortex. J Steroid Biochem Mol Biol. 2019 10; 193:105422.
    View in: PubMed
    Score: 0.040
  36. Carr SB, Kleinschmidt-DeMasters BK, Kerr JM, Kiseljak-Vassiliades K, Wierman ME, Lillehei KO. Negative surgical exploration in patients with Cushing's disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg. 2018 11 01; 129(5):1260-1267.
    View in: PubMed
    Score: 0.038
  37. Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 01; 118(21):5302-9.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)